Actively Recruiting

Phase Not Applicable
Age: 19Years - 80Years
FEMALE
NCT07003841

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

Led by SKIA Inc. · Updated on 2026-03-12

94

Participants Needed

3

Research Sites

71 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial aims to evaluate whether an augmented reality (AR)-based medical imaging solution (SKIA-Breast) is non-inferior to conventional ultrasound-guided skin marking in guiding breast-conserving surgery in female patients with breast cancer. Participants will be randomly assigned in a 1:1 ratio to either the AR-based group or the conventional group. All participants will undergo breast-conserving surgery according to their assigned method. The primary outcome is the negative margin resection rate evaluated by histopathological examination. The secondary outcome is the re-excision rate due to positive margins assessed by histopathological examination.

CONDITIONS

Official Title

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

Who Can Participate

Age: 19Years - 80Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female patients aged 19 to 80 years diagnosed with breast cancer by biopsy
  • Patients who have had MRI, CT, and ultrasound scans
  • Scheduled for breast-conserving surgery without prior neoadjuvant chemotherapy and no metastasis to other organs
  • Tumor size between 5 mm and 30 mm on ultrasound
  • Biopsy pathology confirms invasive carcinoma
  • Presence of a single breast lesion
  • Patients who understand the study and provide written informed consent
Not Eligible

You will not qualify if you...

  • Patients unable to undergo MRI, CT, or ultrasound scans
  • No visible lesions on CT scan
  • Pregnant or breastfeeding women
  • Male patients
  • Patients who received neoadjuvant chemotherapy or have cancer spread to other organs
  • Biopsy pathology shows invasive lobular carcinoma
  • Patients deemed unsuitable by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Ewha Womans University Medical Center

Seoul, Gangseo-gu, South Korea, 07804

Actively Recruiting

2

Seoul National University Hospital

Seoul, Jongno-gu, South Korea

Actively Recruiting

3

Yonsei University Health System, Severance Hospital

Seoul, Seodaemun-gu, South Korea

Actively Recruiting

Loading map...

Research Team

J

Jeongmi LEE

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here